Trial Profile
Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Endoxifen (Primary)
- Indications Advanced breast cancer; Ductal carcinoma; Early breast cancer
- Focus Adverse reactions
- 17 Aug 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 08 Jul 2023 Number of treatment arms have been decreased from 3 to 2 by the removal of Experimental: Endoxifen hydrochloride gel 10 mg daily in Cohorts 1 and 3 arm.
- 18 May 2023 Planned End Date changed from 22 Feb 2023 to 1 Aug 2023.